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Paraskevi VogiatziAbstract
Background: The shortage of suitable organs and achieved tolerance are uncontested main concerns in
transplantation. Long waiting lists for deceased donors and limited numbers of living donors are the current
scenarios. Kidney grafts from living donors have better overall survival compared to cadaveric and require less
aggressive immunosuppressive regimens. The human leukocyte antigen (HLA) labs have the key role to test the
recipient and donors compatibility based on typing and antibody profile. The current standard molecular procedure
in solid organ transplantation is low-resolution typing, at the antigen level.
Main text: In this commentary, the merits of high versus low degree of typing resolution in solid organ
transplantation are discussed. Critical questions and reasons to bring high-resolution typing as a routine test in
health system are considered. Specifically, with the introduction of the next-generation sequencing (NGS) in HLA,
the pros and cons in living donation and benefits after deceased donation are critically evaluated.
Conclusion: NGS has the potential to improve the transplant rates and the overall graft survival. Alternative
strategies to increase in demanding the number of transplants are briefly highlighted.
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In the kidney, the choice of living donor transplants of-
fers better long-term outcomes than deceased organ
transplants and the patients receive less aggressive im-
munosuppression [1]. Unfortunately, the living donors
available are not sufficient to cover the urgent need of
transplants and for other organs, such as the liver, pan-
creas, heart, lung, and the deceased donation path is un-
avoidable. The existent system of organ donation in the
USA based on antigen-based mismatch acceptability,
obtained from low-resolution typing of recipients and
donors, is not working efficiently. For example, the num-
ber of active wait-listed kidney transplant candidates is
over 75,000 in 2015. The average waiting time for a kid-
ney transplant is about 5 years. Many patients are re-
moved from the waiting list because they are too sick toCorrespondence: Paraskevi.Vogiatzi@gmail.com
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Main text
Human leucocyte antigen (HLA) genes code for proteins
playing a key role in immune responses and are notori-
ous for being the most variable in the human genome.
HLA gene sequences show high degree of polymorph-
ism, not adequately captured by traditional typing tests,
such as reverse sequence-specific oligonucleotide probes
(SSOP), sequence-based typing (SBT), which is a Sanger
sequencing reaction, and sequence-specific primers
(SSP). For that reason, a committee from the American
Society for Histocompatibility and Immunogenetics
(ASHI) focused on a list of common and well-
documented (CWD) HLA alleles, with a frequency
greater than 0.001 in reference populations of at least
1500 individuals and reported more than three times in
unrelated individuals, respectively, and rare alleles as
well [3–5]. Many of these alleles have only been partiallyistributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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complete alleles, as published in the International Im-
MunoGeneTics project (IMGT)/HLA database, is most
often limited to exons that code for the extracellular do-
mains of the mature protein. The above mentioned tests
often result in ambiguities since they provide only seg-
ments of HLA genes and fail to distinguish among dif-
ferent alleles suggested by a given sequence and/or
define polymorphisms lying outside the amplified region.
Furthermore, preliminary molecular testing is often
followed by a second level of reflexive and confirmatory
typing, increasing costs and time.
In order to achieve allele information, a higher degree
of resolution is offered by a combination of conventional
SBT and also SSP to resolve ambiguities and/or confirm
rare alleles. The highest possible resolution, covering the
full HLA genomic region, is provided by various next-
generation sequencing (NGS) platforms, which are avail-
able in the market right now, such as Roche GS 454
FLX, Ion Torrent PGM, Illumina MiSeq/HiSeq (Fig. 1),
and Pacific Biosciences SMRT (Table 1). The MiSeq
platform offers higher resolution HLA typing results,
faster, less expensive, and easier work flow compared to
Sanger and other NGS tools. The overall turnaround
time is very comparable between Ion Torrent, MiSeq,
and PacBio. The complexity of sample preparation is
higher with PGM and PacBio, while the actual sequen-
cing time is longer with MiSeq. PacBio is an excellent al-
ternative technology to MiSeq with long read lengths
but the equipment is very expensive. By the application
of the NGS platforms, the list of HLA alleles increases
dramatically [6, 7]. In the bone marrow work-up, be-
cause of the high cost of using high-resolution typing
methodologies, the donors are typed at low- or
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Fig. 1 An overview of DNA sequencing by synthesis technology (Illumina).
specialized oligonucleotides, are bound to both 5′ and 3′ DNA fragment en
into a flow cell that is a glass slide with one (for MiSeq technology) or eigh
with surface-bound, adapter-complimentary oligos. The sample is hybridize
through bridge amplification until the cluster has 1000 copies. Each cluster
imaged, and the emission from each image is recorded. Finally, the reads aresolution SBT, SSP testing to assess compatibility for
best recipient-donor pairs before the transplant process.
With the above NGS methods, no additional typing will
be necessary to assess compatibility since the donors are
typed at the allele level from the very beginning.
Duquesnoy et al. discuss the positive impact of high-
resolution typing in highly sensitized patients awaiting
living donor transplants [8]. This important publication
voices the opinion of academic clinicians, lab directors,
and transplant surgeons in the USA, Canada, and the
UK that emphasize the benefits of high-resolution HLA
typing. The use of low-resolution typing in solid organ
transplant candidates is not efficient when we handle sit-
uations, such as patients with antibody profile with a
broad shared epitope Bw4 or in cases with mismatches
of alleles that are not present in the Luminex single anti-
gen bead (SAB) panel. In order to find the suitable
donor for a recipient, epitope analysis becomes neces-
sary to identify the amino acid structure corresponding
to the epitope of alleles not found in SAB. Many times,
we also have to run different vendors’ tests in parallel to
better characterize or confirm the existence of HLA-DR,
HLA-DQ, and HLA-DP antibodies.
On the other hand, another conservative approach
from experienced HLA laboratory directors is against
the use of high-resolution typing methods as routine use
in solid organ transplantation because they believe it is
more expensive than a low-resolution typing/virtual
crossmatch and will block the organ offers preemptively
[9]. The waiting list for available organs is long, even
longer if the patients are highly sensitized, and adding
more complexity with high-resolution typing tests is not
a priority and will not be helpful for the patients.
The debate is especially important since it revolves on




After random fragmentation of genomic or cDNA, adapters, which are
ds, allowing ligation and NGS library preparation. The library is loaded
t lanes (for HiSeq, allowing eight independent experiments) coated
d onto the flow cell, generating a cluster and is clonally amplified
on the flow cell produces a single sequence read. The flow cell is
re aligned to a reference sequence using bioinformatics tools
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homogeneous populations, but since in the USA this is
seldom the case, allele-based information by high-
resolution typing is recommended. Epitope fine analysis
could offer important insight in the case of rare alleles
and/or alleles, not present in SAB panel, which share
epitope(s) with common alleles. The use of tables with
haplotype frequencies in various populations like those
available from National Marrow Donor Program (NMDP)
is also necessary for other transplants. Furthermore, the
calculated Panel Reactive Antibody (cPRA) in the USA,
which is essential for organ allocation, does not includeTable 1 Comparison of the most common NGS tools and Sanger seDQA, DPA, and DPB antigens in contrast with the
Canadian cPRA [10]. The current cPRA in the USA
underestimates the unacceptable antigens reported in
United Network for Organ Sharing (UNOS), misguid-
ing selection of appropriate donors. High-resolution
typing of the candidates for solid organ transplant-
ation will provide sufficient information for all HLA
loci helping in the generation of accurate critical alert
systems at the transplant centers, if needed, when impos-
sible to include in UNOS. It will decrease the errors in
donor selection process and will favor the correct inter-
pretation of unexpected positive crossmatches.quencing
Table 1 Comparison of the most common NGS tools and Sanger sequencing (Continued)
The cost analysis is presented in US dollars. List pricing may vary between countries and/or sales territories
N/A not applicable
aCost depending on the chip used, i.e., the 314 offers the lowest price ($838) but has the most expensive run ($22.5)
bThe PacBio uses a chip called SMRT or Single-Molecule Real-Time. The single-read accuracy is ~87 %, whereas the consensus accuracy has been seen at 99.999 %
cThe 454 sequencing platform will not be supported after 2016. The consensus accuracy is 99.997 % estimated at 15× coverage of E. coli
dSOLiD4: 99.999 % consensus accuracy at 15× coverage
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in both bone marrow and solid organ transplantation, I
would encourage the use of the best tool available for
high-resolution typing, i.e., next-generation sequencing.
It is true that NGS provides an enormous amount of
genetic information; hence, the HLA clinical labs need
to train the medical technologists investing on a new
technology, hire biostatisticians, and pass strict valid-
ation procedures and the accreditation process. None-
theless, effective analysis and interpretation through
NGS will offer a complete, unambiguous, highest degree
resolution typing of our patients. Overall, a complete
genomic characterization of new HLA alleles andcomplete sequence of the existing, though so far only
partially sequenced, alleles will be obtained.
NGS typing for recipients through hematopoietic stem
cell and living solid organ transplantations is available in
about 3 days. NGS technology is faster than the combin-
ation of traditional tests (SSOP, SBT, and SSP) till now
used and confirmatory typing requested for the final pair
recipient-donor in bone marrow field. It produces unam-
biguous results with no need or lesser need to report
NMDP coding. Currently, the above technologies are
cost-equivalent but NGS would be more robust and also
cheaper if more samples are run (Table 1). A highly sen-
sitized patient awaiting a living kidney donor needs
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at a better clinical outcome. Unsensitized pre-transplant
renal recipient may not consider NGS testing although it
can be a useful post-transplant, i.e., with the presence
of de novo anti-HLA class II donor-specific antibodies
(DSA) [11].
For transplants of organs from deceased donors, quick
typing of donor samples takes place at the local Organ
Procurement Organizations (OPO) using real-time PCR
or frozen prepared reverse SSOP trays, and high-
resolution typing is usually unavailable [12]. This causes
uncertainty in reporting DSA and virtual crossmatching.
Post-transplant NGS still can be retrospectively useful if
questions are raised to identify missed DSA in a graft
dysfunction, interpret biopsy data, better manage the
recipient, avoid infectious complications, and evaluate
the possibility of another living or deceased donor
transplant.
Conclusion
Allele-based mismatch acceptability is a keystone of
solid organ transplantation immunology. This task can
now take advantage of high-resolution typing. The focus
of this commentary is specifically the application of NGS
technology in clinical setting. While providing an over-
whelming amount of information for the patient and do-
nors, NGS will fill the gaps in HLA genomic regions
that were previously uncharacterized. Its routine use in
healthcare would benefit our patients finding suitable
living donors with a single technology, in a single run,
and with more chance of long-term success for the
transplant. Until NGS is able to provide data in few
hours, it will not be used for deceased donor selection.
This means that the other typing methods will continue
to be used, when needed, and nothing will be discarded.
The laboratory director has discretion to judge the need
for NGS or Sanger sequencing and make different deci-
sions based on the patient’s degree of sensitization and
the solid organ (i.e., show flexibility to candidate seeking
a simultaneous liver/kidney transplant with HLA class I
antibodies) [13]. In any case, I would suggest, for the
labs that will not adopt the NGS technology immedi-
ately, that the lab director and the supervisors begin a
self-education process. Furthermore, the requested rigor-
ous validation studies for NGS have discouraged many
labs so far. It will be helpful if the companies providing
NGS platforms further optimize their products and if
the accreditation committees become more collabora-
tive. In the era of personalized medicine, NGS will help
understand how specific individuals respond to infec-
tious diseases, to vaccinations, and to particular im-
munosuppressive drugs.
The transplantation process should be seen in various
directions: ABO blood group incompatible transplantsfor recipients of less than 24 months, dual kidney en
bloc transplants from pediatric deceased donors, domino
transplants, minimally invasive robotic surgery trans-
plants for obese patients with body mass index (BMI)
over 35 previously denied transplant, as well as the use
of rejection prediction from assays, such as the Kidney
Solid Organ Response Test (kSORT) [14–17]. Early in-
volvement of the 58 federally supported OPOs in the
USA is essential in organ transplantation with offers
from cadaveric donors. In addition, an appropriate med-
ical management of the deceased donors would increase
significantly the donation opportunities. Since the live
donor transplantation is the best treatment offer, strong
educational programs led by highly committed physi-
cians, coordinators, and advocates could help remove
misconceptions about the living donation [18].
This is the time to view transplantation issues with
new lenses and invest in novel technologies, combining
efforts of transplant teams to increase organ availability
and suitability. The contribution of the next-generation
sequencing in the donor selection process should not be
ignored.
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